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Objectives. This study sought to determine the effect of antiox-
idant supplementation on the susceptibility of low density lipopro-
tein (LDL) to oxidation in patients with established cardiovascu-
lar disease (CVD).
Background. Data are inconsistent regarding the role of anti-
oxidant nutrients in the prevention of CVD.
Methods. The study design was a 12-week, double-blind,
placebo-controlled clinical trial. Patients with CVD (n 5 45) were
randomized to 1) placebo control; 2) 400 IU of vitamin E, 500 mg
of vitamin C, 12 mg of beta-carotene (mid-dose); or 3) 800 IU of
vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high
dose) daily. Reduced susceptibility of LDL to oxidation was
estimated by an increase in lag phase (minutes). Baseline and 6-
and 12-week measurements of lipoproteins and lag phase were
obtained. Plasma levels of antioxidants were measured at baseline
and 12 weeks.
Results. Concentrations of alpha-tocopherol, vitamin C and
beta-carotene significantly increased in the mid- and high dose
groups during the trial. Lag phase significantly increased from
baseline (190.1 6 63.8 min [mean 6 SD]) to 12 weeks (391.1 6
153.0 min) in the high dose group (p < 0.01). A nonsignificant
increase in lag phase in the mid-dose group was observed during
the same time interval. A dose response was found for mean
percent change from baseline to 12 weeks for lag phase for the
placebo, mid- and high dose groups (p 5 0.004 for trend).
Conclusions. A high dose combination of antioxidant nutrients
reduces the susceptibility of LDL to oxidation in patients with
CVD and may be useful in secondary prevention.
(J Am Coll Cardiol 1997;30:392–9)
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Despite significant reductions in risk factor levels and advances
in medical and surgical intervention, cardiovascular disease
(CVD) remains the leading cause of death in the United States
(1). The risk of future cardiovascular events is substantially
increased in subjects with established CVD compared with
those without previous manifestations of clinical disease (2).
Therefore, it is important to identify effective strategies for the
secondary prevention of coronary artery disease (CAD).
Recent data suggest that antioxidant nutrients may play a
role in the prevention of CAD. The protective effect of
antioxidant nutrients may be mediated through inhibition of
the oxidative modification of low density lipoprotein choles-
terol (LDL), which is believed to be a key step in the
pathogenesis of atherosclerosis (3,4). In addition, antioxidants
may reduce platelet adhesiveness (5), preserve endothelial
function (6) and stabilize plaque (7). These mechanisms lend
support for a role of antioxidants in the prevention of athero-
sclerosis and thrombosis and in the regulation of vasomotor
tone.
Epidemiologic data have shown associations between anti-
oxidant intake and reduced CVD in several prospective studies
(8–15). Data from randomized clinical trials have not sup-
ported the findings from observational studies. A Finnish trial
(16), designed to test the effect of low dose alpha-tocopherol
(50 mg) or beta-carotene (20 mg/day), or both, on the inci-
dence of lung cancer in 29,133 male smokers, failed to show a
protective effect of antioxidants on death from CVD. Recent
results from large, randomized clinical trials showed no effect
of beta-carotene alone (Physician’s Health Study [17], Skin
Cancer Prevention Study [18]) or in combination with retinol
(Carotene and Retinol Efficacy Trial [19]) in the primary
prevention of CVD.
Few data are available to evaluate the role of antioxidant
nutrients in secondary prevention. A subgroup analysis of the
Cholesterol Lowering Atherosclerosis Study (CLAS) study
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(11) demonstrated an association between supplemental vita-
min E intake and a reduction in coronary lesion progression
by angiography. The Cambridge Heart Antioxidant Study
(CHAOS) (20), a secondary prevention trial of 2,002 patients
with CAD followed up for a median of 510 days demonstrated
a 77% reduction in nonfatal myocardial infarction in patients
randomized to receive either 400 or 800 IU of vitamin E versus
those receiving placebo.
Experimental evidence (21–30) demonstrating favorable
alterations in indexes of oxidized LDL in subjects treated with
antioxidant supplements provides biologic plausibility for a
role of dietary micronutrients in CVD prevention. These data
are limited to patients free of disease, and the generalizability
of results to patients with CVD remains unclear. Patients with
CVD have unfavorable indexes of oxidized LDL compared
with healthy control subjects, and it may not be appropriate to
extrapolate doses of antioxidant vitamins to be used in second-
ary prevention trials on the basis of data obtained from
subjects without CVD (31–33).
This purpose of the present study was to test the effect of
two doses of a combination of vitamin E, vitamin C and
beta-carotene on lag phase, a surrogate measure of the sus-
ceptibility of LDL to oxidation, compared with placebo in a
randomized clinical trial in subjects with established CVD.
Methods
Subjects. Forty-five nonsmoking, nondiabetic subjects (39
men, 6 women; 39 to 80 years old) with established CAD were
recruited from the cardiac catheterization laboratory and the
preventive cardiology program at the University of Michigan
Medical Center between January 1994 and May 1995. CAD
was determined by angiography (at least one lesion .70%
lumen stenosis), previous angioplasty, coronary artery bypass
graft surgery, myocardial infarction by history validated by
electrocardiographic changes or classic angina with an isch-
emic response on a treadmill test. Subjects had to have been on
a stable diet and exercise program for 6 months and have
normal hepatic and renal function, no evidence of malabsorp-
tion, pancreatic or biliary disease and no acute medical condi-
tion for at least 3 months before study entry. Patients currently
receiving resin therapy or using vitamin supplements above the
recommended dietary allowance (RDA) levels within the
previous 6 months were excluded from the study. There were
no exclusion criteria based on serum lipid status. All subjects
gave informed consent. The study was approved by the Insti-
tutional Review Board of The University of Michigan Medical
Center.
Experimental protocol. After baseline measurements, sub-
jects were entered into a 12-week double-blind, placebo-
controlled clinical trial. Each subject was randomly assigned to
receive 1) placebo (control group, n 5 15); 2) 400 IU of
vitamin E, 500 mg of vitamin C, and 12 mg of beta-carotene
daily in two divided doses (mid-dose group, n 5 15); or 3) 800
IU of vitamin E, 1,000 mg of vitamin C and 24 mg of
beta-carotene daily in two divided doses (high dose group, n 5
15). Supplements were given in the form of a capsule (vitamin
E [200 IU] as DL-alpha-tocopheryl acetate, vitamin C [250 mg]
and beta-carotene [6 mg]) obtained as a gift from Hoffmann-
La Roche Inc. Each subject took two capsules (supplement or
placebo, or both) twice a day to maintain blinding. Pill counts
were done at 6 and 12 weeks to assess adherence to study
protocol. Four subjects did not complete the trial (one assigned to
the placebo group who had an adverse effect of headache within
2 weeks of the trial; one assigned to the high dose group who had
an adverse effect of stomach discomfort after 1 week of therapy;
two who did not return after the baseline visits because of
scheduling difficulties). All 41 subjects who completed the trial
were 100% compliant with the study medication.
Laboratory protocol. Two lipid, lipoprotein and lag phase
measurements were obtained 1 week apart immediately before
study entry and were averaged to obtain baseline values. One
laboratory measurement was done at study midpoint (6
weeks). Two ending measurements were done at 11 and 12
weeks and were averaged to obtain the 3-month follow-up
laboratory values. Plasma tocopherol, carotenoid and vitamin
C levels were measured once at baseline and again at 12 weeks
in subdued light at the time of other laboratory measurements.
After a 12-h fast and a 15-min supine rest period, one 20-ml
tube without anticoagulant and two 12-ml heparinized tubes of
blood were obtained with the tourniquet deflated. Whole
blood without anticoagulant was centrifuged at 2,000 rpm for
30 min to separate serum. Aliquots of serum samples were
frozen at 215°C for up to 4 weeks for serum lipid and
lipoprotein lipid analysis, and fresh serum was used for LDL
lag phase assay.
Heparinized blood was separated by refrigerated centrifu-
gation at 2,300 3 g for 10 min. Plasma aliquots designated for
tocopherol and carotenoid quantification were preserved in
sodium ascorbate and stored at 270°C in cryogenic tubes for
up to 6 months. One-milliliter aliquots designated for vitamin
C analysis were processed with 10% trichloroacetic acid before
freezing to enhance stability during short-term storage.
Measurement of lipids, lipoproteins and lag phase. For
measurement of lag phase, LDL was isolated immediately
from fresh serum according to the method of Weiland and
Seidel (34). This method highly correlates (r 5 0.9) with results
obtained from ultracentrifugation to isolate LDL.
The oxidation of polyunsaturated fatty acids in a buffer
Abbreviations and Acronyms
ANOVA 5 analysis of variance
BMI 5 body mass index
CAD 5 coronary artery disease
CVD 5 cardiovascular disease
HDL 5 high density lipoprotein
HDL-C 5 high density lipoprotein cholesterol
HPLC 5 high performance liquid chromatography
LDL 5 low density lipoprotein
LDL-C 5 low density lipoprotein cholesterol
TC 5 total cholesterol
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system was continuously monitored at 234 nm with a Beckman
DU-6 spectrophotometer up to 10 h according to the method
of Esterbauer et al. (35). Lag phase is expressed in minutes and
is the time interval from addition of Cu21 ions to the onset of
the propagation phase of LDL oxidation, which is the maximal
rate of conjugated diene production. Lag phase is determined
by extrapolating a tangent drawn from the slope of the most
rapid rise in the absorbance curve to the horizontal time axis.
Lag phase is indicative of the resistance of LDL to oxidation;
the greater the resistance of LDL to oxidation, the longer the
lag phase.
Cholesterol and triglyceride concentrations were deter-
mined enzymatically with commercially available reagents
(Sigma) by the methods of Allain et al. (36) for total choles-
terol (TC), LDL cholesterol (LDL-C), high density lipoprotein
cholesterol (HDL-C) and McGowan et al. (37) for TC, LDL-
triglycerides. The isolation of LDL-C was according to the
method of Weiland and Seidel (34). HDL-C was isolated by
precipitation with phosphotungstic/MgCl2 according to the
method of Assmann et al. (38).
Plasma antioxidant measurements. Plasma carotenoids
were separated and quantified according to the high perfor-
mance liquid chromatographic (HPLC) method of Bieri et al.
(39), as modified by Craft et al. (40) and Craft (41) with further
modifications to reduce oxidative loss and improve recovery of
compounds during analysis. This analytic method measures
90% of the total plasma carotenoids present and permits
quantification of the predominant serum carotenoids, includ-
ing beta-carotene.
Plasma tocopherols were separated and quantified accord-
ing to the HPLC method of Bieri et al. (42). This analytic
method permits separation and quantification of alpha- and
gamma-tocopherol, using tocopherol acetate (Sigma) as an
internal standard. Plasma vitamin C was measured by the
derivative spectrophotometric method of Omaye et al. (43).
Measurement of covariates. Demographic variables, life-
style habits and medication usage were assessed by standard-
ized questionnaire. Anthropometric and physiologic variables
were evaluated based on a standard examination. Body fat was
calculated from three gender-specific skinfold measurements
using the generalized equations of Jackson and Pollock (44)
and Jackson et al. (45) for predicting body density.
Detailed dietary histories based on 3-day food records were
obtained by a nutritionist 1 week before study entry and during
the final week of the study. Diet records were analyzed using
Nutritionist IV software (version 2.1 1995 N-Squared comput-
ing). Average daily total energy intake, percent energy from
fat, percent energy from saturated fat, percent energy from
carbohydrate, percent energy from protein and grams of
alcohol/day and intake of antioxidants were determined at the
beginning and end of the study.
Statistical analysis. Statistical analysis was performed
based on intention to treat. Continuous variables are expressed
as mean value 6 SD. Normal probability plots of all continu-
ous variables were examined, and the Shapiro-Wilk statistic
was used to test for normal distribution. Data that were not
normally distributed, including lag phase, was log transformed
when appropriate. Within-group change for lipids, plasma
antioxidants and lag phase during the treatment period were
evaluated using paired t tests. Between-group differences at
baseline and 6 and 12 weeks for lipids, plasma antioxidants and
lag phase were evaluated by analysis of variance (ANOVA)
with a Tukey test to control for multiple pairwise comparisons.
The relations between continuous variables were evaluated
using Pearson correlation coefficients or Spearman correla-
tions when data were not normally distributed. Differences in
mean values for dichotomous variables were examined by
Student t tests or Wilcoxon rank sum for nonnormally distrib-
uted variables. Significant independent predictors of lag phase
were incorporated into a multiple linear regression model to
assess the independence of antioxidant supplementation on
resistance of LDL-C to oxidation. All tests were two-tailed,
and statistical significance was set at p , 0.05. All data were
double entered, discrepancies were corrected, and analysis was
performed using SAS for Windows version 6.08 (1992 SAS
Institute, Inc.). Blinding was maintained until the analysis was
complete. The study was designed to detect a 10% difference in
LDL oxidation with 80% power at p 5 0.05.
Results
Patients. Descriptive information for the 45 subjects with
CAD is shown in Table 1. The only statistically significant
difference between groups for any of the variables was the use
of beta-adrenergic blocking agents. In the placebo group,
seven subjects reported current use of beta-blockers use com-
pared with four in the mid-dose group and one in the high dose
group.
Lipid profiles. Mean baseline and 6- and 12-week lipid
profiles, according to group assignment, are presented in Table
2. There were no significant differences in baseline TC,
LDL-C, HDL-C or triglyceride levels between groups. In the
placebo group, HDL-C increased from 0.90 mmol/liter at
baseline to 1.02 mmol/liter (p , 0.05) from baseline to 6 weeks.
In the high dose group, TC and LDL-C significantly increased
between 6 and 12 weeks, from 5.64 to 6.08 mmol/liter and from
4.09 to 4.56 mmol/liter, respectively. HDL-C increased be-
tween 6 and 12 weeks, from 0.99 to 1.08 mmol/liter (p , 0.05)
in the high dose group. LDL-C and triglycerides increased
significantly from baseline to 12 weeks in the high dose group,
from 3.86 to 4.56 mmol/liter and from 1.75 to 2.07 mmol/liter,
respectively.
Plasma antioxidants. Within-group changes. Plasma con-
centrations of alpha-tocopherol, vitamin C and beta-carotene
were 24.43 6 7.06, 71.94 6 36.34 and 0.29 6 0.17 mmol/liter,
respectively, at baseline and did not significantly change at 12
weeks in the placebo group (Fig. 1). Results were unchanged
when plasma alpha-tocopherol was lipid standardized. Alpha-
tocopherol levels increased twofold during the trial in the
mid-dose group, from 28.63 6 7.7 to 60.57 6 17.4 mmol/liter
(p , 0.01), and threefold in the high dose group, from 27.39 6
10.10 to 88.72 6 47.85 mmol/liter (p , 0.01). Vitamin C levels
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increased 1.5 fold in the mid-dose group, from 73.13 6 36.34 to
107.31 6 28.95 mmol/liter (p , 0.05), and nearly twofold in the
high dose group, from 61.95 6 22.14 to 118.67 6 35.77
mmol/liter (p , 0.01). Beta-carotene levels also significantly
increased with supplementation in the mid- and high dose
groups, from 0.34 6 2.01 to 1.99 6 1.17 mmol/liter (p , 0.01)
and from 0.29 6 0.1 to 3.01 6 1.5 mmol/liter (p , 0.05), nearly
six- and tenfold, respectively.
Between-group changes. A significant between-group differ-
ence at 12 weeks for plasma concentrations of alpha-
tocopherol was observed (p 5 0.0001, ANOVA), with signifi-
cant pairwise comparisons between mid-dose versus placebo,
high dose versus placebo and high versus mid-dose. Beta-
carotene levels were significantly different between groups at
12 weeks (p 5 0.0001, ANOVA), with significant pairwise
comparisons between placebo versus mid-dose and placebo
versus high dose. No statistically significant between-group
differences were noted for vitamin C at 12 weeks (p 5 0.057).
However, the between-group differences for change from
baseline to 12 weeks were significant for vitamin C (p 5
0.0001), which was attributable to a significant pairwise com-
parison for high dose versus placebo. Both alpha-tocopherol
and beta-carotene plasma levels showed significant between-
group changes over time for high dose versus placebo and mid
dose versus placebo (p , 0.05).
Lag phase. Within-group changes. Table 2 also describes
the change in lag phase after treatment at 6 and 12 weeks
according to group assignment. In the placebo group, there is
a significant increase in lag phase between baseline and 6
weeks, from 219.5 6 69.4 to 258.2 6 77.0 min (p , 0.01), with
no significant increase at 12 weeks (256.8 6 73.8 min) com-
pared with that at baseline or 6 weeks. The mid-dose group
experienced an increase in lag phase between baseline and 6
weeks, from 182.0 6 100.6 to 267.1 6 76.3 min (p , 0.01) and
between 6 and 12 weeks, from 267.1 6 76.3 to 311.8 6
112.5 min (p , 0.01). The high dose group had a significant
increase in lag phase at 12 weeks (391.1 6 153.0 min)
compared with that at 6 weeks (239.1 6 97.3, p , 0.01) and
baseline (190.1 6 63.8 min, p , 0.01). There was no statisti-
cally significant increase in lag phase between baseline and 6
weeks.
Between-group changes. Lag phase did not differ signifi-
cantly between treatment groups or placebo at baseline or at 6
weeks. At 12 weeks there was a significant between-group
difference in mean lag phase (p 5 0.02, ANOVA). The change
in lag phase from baseline to 6 weeks did not differ between
groups, but the change from baseline to 12 weeks did differ
(p 5 0.04, ANOVA).
Figure 2 illustrates a significant dose response for mean
percent change in lag phase between the treatment groups
from baseline to 12 weeks (p 5 0.004 for trend). The mean
percent increase in lag phase from baseline to 12 weeks in the
mid-dose group was 71% compared with a doubling of lag
phase in the high dose group. The mean percent change in lag
phase from baseline to 12 weeks was highly correlated with
Table 1. Characteristics of 45 Study Participants With Coronary
Artery Disease
Male 39 (87.0)
White 43 (95.6)
Previous MI 18 (40.0)
Previous CABG 23 (51.1)
CAD $3 vessels* 23 (73.5)
Hx of hypertension 22 (48.9)
Hx of abnormal cholesterol 41 (91.1)
Former smoker 24 (53.3)
Family Hx of premature CAD 19 (43.2)
Sedentary 8 (17.8)
Regular wine use 35 (77.8)
Multivitamin use 10 (23.3)
Beta-blocker use 12 (26.7)
Lipid-lowering drugs† 24 (53.3)
Age (yr) 60.56 6 8.7
BMI (kg/m2) 28.39 6 4.1
Heart rate (beats/min) 64.93 6 11.0
Body fat (%) 30.16 6 4.8
TC (mmol/liter) 5.67 6 1.1
LDL-C (mmol/liter) 3.87 6 1.2
HDL-C (mmol/liter) 1.00 6 0.2
Triglycerides (mmol/liter) 1.56 6 0.6
*Information from cardiac catheterization available for 31 subjects. †In-
cludes HMG-CoA reductase inhibitors (n 5 17), fibric acid derivatives (n 5 5)
and nicotinic acid (n 5 2). Data presented are mean value 6 SD or number (%)
of patients. BMI 5 body mass index; CABG 5 coronary artery bypass graft
surgery; CAD 5 coronary artery disease; HDL-C 5 high density lipoprotein
cholesterol; Hx 5 history; LDL-C 5 low density lipoprotein cholesterol; MI 5
myocardium infarction; TC 5 total cholesterol.
Table 2. Mean Baseline and 6- and 12-Week Lipid Profiles According to Treatment Group
Placebo Mid-Dose High Dose
Baseline 6 Wk 12 Wk Baseline 6 Wk 12 Wk Baseline 6 Wk 12 Wk
TC (mmol/liter) 5.27 6 0.67 5.11 6 0.70 4.79 6 0.90 5.98 6 1.08 5.69 6 0.97 5.88 6 1.05 5.76 6 1.39 5.64 6 0.99 6.08 6 1.32*
LDL-C (mmol/liter) 3.62 6 0.57 3.57 6 0.50 3.33 6 0.76 4.12 6 1.16 4.08 6 1.01 4.32 6 0.98 3.86 6 1.55 4.09 6 1.17 4.56 6 1.23*†
HDL-C (mmol/liter) 0.90 6 0.18 1.02 6 0.21† 1.00 6 0.27 1.12 6 0.29 1.13 6 0.30 1.13 6 0.28 0.99 6 0.18 0.99 6 0.17 1.08 6 0.27*
Triglycerides (mmol/
liter)
1.46 6 0.43 1.29 6 0.42 1.32 6 0.43 1.45 6 0.49 1.65 6 0.50 1.51 6 0.47 1.75 6 0.71 1.88 6 0.79 2.07 6 1.25†
Lag phase (min) 219.5 6 69.4 258.2 6 77.0† 256.8 6 73.8 182.0 6 100.6 267.1 6 76.3† 311.8 6 112.5† 190.1 6 63.8 239.1 6 97.3 391.1 6 153.0*†
*p , 0.05, significant increase from 6-week measure. †p , 0.05, significant increase from baseline measure. Data presented are mean value 6 SD. Abbreviations
as in Table 1.
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mean percent change in plasma alpha-tocopherol (r 5 0.48,
p 5 0.002) and beta-carotene (r 5 0.49, p 5 0.002).
No significant within or between-group differences at base-
line or at 12 week follow-up were noted for dietary intake of
antioxidant nutrients, total calories, percent energy from fat,
saturated fat, carbohydrate, protein or grams of alcohol/day.
Predictors of lag phase. No statistically significant dichot-
omous predictors of lag phase were identified. Continuous
predictors of lag phase are shown in Table 3. The only
significant lipid predictor of lag phase was LDL-C (r 5 20.39,
p 5 0.01). Significant inverse correlations existed for body
mass index (r 5 20.33, p , 0.05), heart rate (r 5 20.34, p ,
0.05) and percent body fat (r 5 20.41, p , 0.01). Only heart
rate retained significance when univariate predictors were
examined in multiple regression models controlling for age,
gender and LDL-C at 12 weeks and LDL-triglycerides. Heart
rate was significantly associated with beta-blocker use (p 5
0.02); however, heart rate still was a significant predictor of lag
phase when beta-blocker use was controlled for in a multiple
regression model (p 5 0.02).
Figure 1. Mean change (with 95% confidence
intervals) from baseline (gray bars) in plasma
alpha-tocopherol, vitamin C and beta-carotene
levels after 12 weeks of supplementation (solid
bars) with 800 IU of vitamin E, 1,000 mg of
vitamin C and 24 mg of beta-carotene (high
dose) or 400 IU of vitamin E, 500 mg of vitamin
C and 12 mg of beta-carotene (mid-dose) versus
placebo.
Figure 2. Mean change from baseline in lag
phase after 12 weeks of supplementation with
800 IU of vitamin E, 1,000 mg of vitamin C and
24 mg of beta-carotene (high dose) or 400 IU of
vitamin E, 500 mg of vitamin C and 12 mg of
beta-carotene (mid-dose) versus placebo. p 5
0.004 for trend.
396 MOSCA ET AL. JACC Vol. 30, No. 2
ANTIOXIDANT VITAMINS REDUCE LDL OXIDATION August 1997:392–9
Supplementation with a combination of vitamin E (800 IU),
vitamin C (1,000 mg) and beta-carotene (24 mg) was a
significant predictor of lag phase in multiple regression models
controlling for age and gender (p 5 0.008, model R2 5 0.21).
When heart rate and beta-blocker use were added to the
model, high dose group assignment still remained a significant
predictor of lag phase (p 5 0.02, model R2 5 0.23).
Discussion
The major finding of our study was a significant reduction in
the susceptibility of LDL-C to oxidation in patients with CVD
supplemented daily for 12 weeks with a combination of 800 IU
of vitamin E, 1,000 mg of vitamin C, and 24 mg of beta-
carotene 24 daily compared with placebo. In addition, we
observed a significant dose response for this high dose combi-
nation compared with a combination of 400 IU of vitamin E,
500 mg of vitamin C and 12 mg of beta-carotene and a placebo
control.
This finding is consistent with data from a study by Jialal
and Grundy (25) who observed a reduction in the rate of LDL
oxidation in 24 healthy men given 800 IU of DL-alpha-
tocopherol in the form of soy bean capsules compared with
placebo. In their study, indexes of oxidized LDL, time course
curves of thiobarbituric acid-reacting substances (TBARS)
activity or conjugated diene formation were significantly lower
among treated subjects at 6 and 12 weeks than at baseline. We
did not detect significant between-group differences until 12
weeks. This finding suggests that a longer exposure to antiox-
idant nutrients may be necessary to protect LDL against
oxidation in patients with CVD compared with healthy subjects
and may be important in the design of future studies of
antioxidant supplementation in patients with CVD or those
with cardiovascular risk factors because these groups may have
significant biologic variability in response to antioxidant sup-
plementation. An alternative explanation for the lack of a
significant treatment effect at 6 weeks may be the significant
increase in lag phase that was observed in our control group at
6 weeks.
We chose lag phase to evaluate the effect of antioxidant
supplementation on LDL oxidation as opposed to measure-
ment of the products of peroxidation or the maximal rate of
oxidation. Lipophilic antioxidants, such as vitamin E and
beta-carotene, are carried in LDL and may protect polyunsat-
urated fatty acids against oxidation by competing with them for
free radicals. Once antioxidants are depleted from LDL, the
propagating chain reaction of lipid peroxidation ensues, so an
increase in the amount of antioxidants in LDL would be
expected to delay the onset of this process. Change in lag phase
is most likely the most appropriate measure of the effect of
antioxidant vitamin supplementation on LDL oxidation be-
cause it reflects altered susceptibility of the LDL particle to
oxidation.
In a more recent dose–response study by Jialal et al. (22), a
minimal dose of alpha-tocopherol (400 IU) was necessary to
prolong lag phase in 48 healthy men after 8 weeks of vitamin E
supplementation ranging from 60 to 1,200 IU daily. Our
mid-dose group, which included 400 IU of alpha-tocopherol
supplementation, did not show a significant prolongation of lag
phase compared with placebo at 12 weeks. This difference may
reflect an increased dose of antioxidant vitamins required to
alter LDL-C oxidizability in patients with CVD or may be due
to a lack of power to detect a difference at that level of
supplementation in our study.
Abbey et al. (29) showed a significant increase in lag time
after 3 months in 45 nonsmoking subjects supplemented with a
daily dose of 18 mg of beta-carotene, 900 mg of vitamin C,
250 mg of D-alpha-tocoheryl succinate (equivalent to 50 mg of
vitamin E) and 12 mg of elemental zinc. Plasma concentrations
of beta-carotene, alpha-tocopherol and ascorbic acid increased
fivefold: 55% and 27%, respectively. We observed similar or
greater changes in plasma antioxidants in our mid-dose group
but did not detect a significant increase in lag phase in that
group compared with the placebo group. This result raises the
possibility that patients with CAD may require more significant
changes in plasma antioxidants to protect the LDL particle
from susceptibility to oxidation relative to that in healthy
subjects. However, this finding should be interpreted with
caution because our power to detect a statistically significant
increase in lag phase in the mid-dose group compared with the
placebo group was low because of the small sample size.
Substantial individual variability in the ability of antioxidants
to protect LDL from oxidation may also exist in patients with
CAD.
Our study was also consistent with a crossover study of eight
healthy, mildly hyperlipidemic volunteers by Reaven et al. (28),
who used in vitro assays of oxidation to show that long-term
supplementation with large doses of vitamin E conferred
increased protection to LDL. A linear increase in LDL alpha-
tocopherol levels up to an intake of 800 IU/day in 20 healthy
nonsmoking volunteers was demonstrated by Princen et al.
(24). Simultaneously, the resistance of LDL to oxidation was
increased in a dose-dependent manner and differed signifi-
cantly from baseline even after ingestion of only 25 IU/day.
The finding of a significant increase in lag phase at 6 weeks
in our placebo control group may have been due to chance. It
is interesting that the trend was similar for all groups and raises
Table 3. Correlation Coefficients for Continuous Predictors of Lag
Phase in 45 Subjects With Coronary Artery Disease
Baseline Continuous Variable r Coeff
Age (yr) 20.28
BMI (kg/m2) 20.33*
Heart rate (beats/min) 20.34*
Body fat (%) 20.42*
TC (mmol/liter) 20.18
LDL-C (mmol/liter) 20.39*
LDL-triglycerides (mmol/liter) 20.10
HDL-C (mmol/liter) 20.16
Triglycerides (mmol/liter) 0.12
*p , 0.05. Coeff 5 coefficient; other abbreviations as in Table 1.
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the possibility that altered lifestyle habits, such as diet, in the
initial phase of the study may have been associated with an
improvement in lag phase in all groups, making it difficult to
detect between-group differences at the 6 week time point.
Beard et al. (46) recently demonstrated an increase in lag
phase in subjects participating in a 3-week residential program
with access to high complex carbohydrate/low fat foods and
formal exercise classes. The significant increase in plasma
levels for all antioxidants at 12 weeks may have been able to
overcome nonpharmacologic effects on lag phase at that point.
Furthermore, we documented no significant within- or
between-group differences in dietary variables at 12 weeks, so
any alterations in dietary habits may have returned to baseline
levels by the conclusion of the study.
An alternative explanation for the significant increase in lag
phase at 6 weeks in the placebo group is the corresponding
significant increase in HDL-C in the placebo group at 6 weeks.
HDL-C is protective for LDL oxidation, and the increase in lag
phase that was observed in the placebo group at 6 weeks may
have been a reflection of the increase in HDL-C that occurred
in the placebo group in that time frame. We were surprised by
the finding that LDL-C and triglycerides were significantly
increased from baseline in the high dose group. Tsai et al. (47)
has reported a significant reduction of serum thyroid hormone
levels and an elevation of serum triglyceride levels in women
receiving supplemental megadoses of vitamin E (600 IU). A
recent review of the safety of vitamin E supplementation (48)
suggests inconsistent effects on serum lipid and lipoprotein
levels. It is unclear whether the lipid alterations that we
observed are adverse or simply reflect conformational changes
in LDL, which we did not evaluate in the present study. The
increase in LDL-C that was observed in the high dose group is
not likely to explain the effect of treatment on lag phase.
LDL-C was inversely related to lag phase, and therefore an
increase in LDL-C would tend to attenuate the effect of
treatment in the high dose group.
The prolongation in lag phase with high dose supple-
mentation of antioxidant nutrients in our study is consistent
with the results of the Cambridge Heart Antioxidant Study
(CHAOS) (20). In that randomized, clinical trial of 2,002
patients with angiographically proven CVD, a nearly 50%
reduction in the combined end point of CVD death and
nonfatal events was demonstrated with supplementation of
vitamin E (400 to 800 IU daily), attributable to a significant
reduction in nonfatal myocardial infarction.
Study limitations. Our study is limited because we used a
combination of antioxidant vitamins, and therefore we cannot
define the relative contribution of each individual component
of the supplement we utilized to the inhibition of LDL
oxidation. Because vitamin E is contained in the LDL particle
at substantially higher concentrations than other antioxidant
nutrients, we speculate that the alpha-tocopherol component
would have a major impact on reducing the susceptibility of
LDL to oxidation. Future studies should address the effects of
vitamin E with and without other antioxidant supplements on
LDL oxidation and other cardiovascular risk factors.
It is unlikely that the powerful effect of antioxidant supple-
mentation on LDL oxidation that we observed can be ex-
plained by selection bias or confounding because this was a
randomized clinical trial, and groups were well matched at
baseline. Although beta-blocker use did differ between groups,
there were no significant differences in baseline lag phase
between groups, and drug usage did not change throughout the
trial. If beta-blockers do confer a protective effect on LDL to
oxidation, our results would be strengthened because the
placebo control group had increased usage of beta-blockers.
Our data suggest that it is heart rate and not beta-blocker use
that is a significant multivariate predictor of lag phase. We
questioned whether this finding may be explained by improved
levels of fitness and attempted to evaluate exercise level as a
predictor of lag phase. We were unable to detect significant
effects of exercise on lag phase, which may be due to our small
sample size and the small range of variation in exercise levels
in our subjects. Future studies should address the role of
exercise and fitness levels in predicting changes in the oxidiz-
ability of LDL.
Conclusions. We demonstrated a significant reduction in
the susceptibility of LDL to oxidation, as evidenced by a
doubling of mean lag phase, in patients with CAD supple-
mented with a combination of vitamin E (800 IU), vitamin C
(1,000 mg) and beta-carotene (24 mg). These data lend
support for a role of antioxidants in secondary prevention;
however, the potential adverse effects of high dose vitamin
supplementation deserves further investigation.
We are indebted to Terri Johnson, Elizabeth Maimon and Leslie Bluman for
assistance with data collection. We are grateful to Jackie Toms for technical
assistance in the preparation of the manuscript, and we sincerely appreciate the
helpful comments and critical review of the manuscript by Kim Eagle, MD.
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